BALAXI PHARMACEUTICALS LIMITED

400 billion

et Targeted Expansion Product Sourcing Regions Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9 Key Milestones Started business supplying white labelled pr

6 billion

cing Regions Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9 Key Milestones Started business supplying white labelled products to customers in Africa Pr

INR 47.57 crore

onduras and El Salvador Successfully completed fund raising exercise through Preferential issue – INR 47.57 crore Capex plans – Project initiated for our first Pharma Formulation manufacturing facility in Hydera

40.19%

enue Gross Profit Gross Margin % EBITDA before exceptional item* Q3 FY25 Q3 FY24 73.29 29.45 40.19% 7.93 60.78 30.42 50.05% 13.53 YoY 20.58% (3.19%) (987 bps) (41.39%) EBITDA Margin % befor

50.05%

rgin % EBITDA before exceptional item* Q3 FY25 Q3 FY24 73.29 29.45 40.19% 7.93 60.78 30.42 50.05% 13.53 YoY 20.58% (3.19%) (987 bps) (41.39%) EBITDA Margin % before exceptional item* 10.81%

20.58%

re exceptional item* Q3 FY25 Q3 FY24 73.29 29.45 40.19% 7.93 60.78 30.42 50.05% 13.53 YoY 20.58% (3.19%) (987 bps) (41.39%) EBITDA Margin % before exceptional item* 10.81% 22.25% (1144 bps)

3.19%

ional item* Q3 FY25 Q3 FY24 73.29 29.45 40.19% 7.93 60.78 30.42 50.05% 13.53 YoY 20.58% (3.19%) (987 bps) (41.39%) EBITDA Margin % before exceptional item* 10.81% 22.25% (1144 bps) Profit

987 bps

m* Q3 FY25 Q3 FY24 73.29 29.45 40.19% 7.93 60.78 30.42 50.05% 13.53 YoY 20.58% (3.19%) (987 bps) (41.39%) EBITDA Margin % before exceptional item* 10.81% 22.25% (1144 bps) Profit After Tax

41.39%

Q3 FY24 73.29 29.45 40.19% 7.93 60.78 30.42 50.05% 13.53 YoY 20.58% (3.19%) (987 bps) (41.39%) EBITDA Margin % before exceptional item* 10.81% 22.25% (1144 bps) Profit After Tax before exc

10.81%

50.05% 13.53 YoY 20.58% (3.19%) (987 bps) (41.39%) EBITDA Margin % before exceptional item* 10.81% 22.25% (1144 bps) Profit After Tax before exceptional item* PAT Margin %* Exceptional Item* 5

22.25%

13.53 YoY 20.58% (3.19%) (987 bps) (41.39%) EBITDA Margin % before exceptional item* 10.81% 22.25% (1144 bps) Profit After Tax before exceptional item* PAT Margin %* Exceptional Item* 5.36 7.3

1144 bps

oY 20.58% (3.19%) (987 bps) (41.39%) EBITDA Margin % before exceptional item* 10.81% 22.25% (1144 bps) Profit After Tax before exceptional item* PAT Margin %* Exceptional Item* 5.36 7.32% - 11.9

“7 Investment in Manufacturing Facilities Setting up its first pharmaceutical formulation manufacturing unit General Oral Solid Dosage (OSD) formulations Targeting demand for high quality products in Latin American markets Allows full backward integration of supply chain Plant Commissioning by the Q1 of FY26 Historically, Balaxi has successfully executed on its “produce, stock and sell” model.”

“Over the medium term, Balaxi sees several new market opportunities opening up for its product lines.”

“Stickler for well-defined systems and processes Initiated and leads the consumer products business 13 FINANCIAL HIGHLIGHTS 14 Management’s Comments “In Q3 FY25, through our strategic efforts to strengthen the distribution network, expand sales channels, and enhance our presence in key sectors such as hospital across Angola, we observed a notable recovery in that market.”

Expansion initiated

1

Expansion initiated

Ecuador, Chile (Latin America) 897 product registrations in Seven countries 300+ registrations submitted or in the pipeline Establishing the Company’s first pharmaceutical formulation facility in Hyderabad Successful process being replicated in other frontier markets; expansion plans in other global markets over near to medium term Centralized digital procurement, regulatory management and customized CRM tools 5 Key Success Factors Market Selection Methodology  Focus on countries with high-potential economic growth framework  Identify non-English speaking countries with similar characteristics  Low competitive intensity and potential to establish top-2 position  On-ground feedback mechanism allows deep understanding of demand dynamics  As population crosses prosperity thresholds, healthcare spends expand exponentially Human Capital Management  Established unique ecosystem of 100+ Indian expatriates in operating geographies  Financial security ecosystem for key personnel, creatin